Released Aug 13, 2012, after the close
10-Q filed Aug 14, 2012, 45 days after period end · 0001019687-12-002787
Q2 2012 · 10-Q
Revenue$6.02K$6.02K −0.9% vs Q2 2011−99.9% vs Q1 2012
Net Income-$633.00K-$633.00K N/M vs Q2 2011N/M vs Q1 2012
EPS Diluted-$0.01-$0.01 N/M vs Q2 2011N/M vs Q1 2012
Operating Income-$643,000N/M
Operating Cash Flowderived$342,000N/M
Free Cash Flowderived-$72,000N/M
Margins · derived
Operating margin-10689.9%+6657.7 pt vs Q2 2011
Net margin-10523.7%+5687.2 pt vs Q2 2011
What the release said
The release
Same quarter
| Metric | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|
| Revenue | $6.02K | $6.07K | $6.19M |
| Net Income | -$633.00K | -$984.00K | -$457.00K |
| EPS Diluted | -$0.01 | -$0.02 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR